-
Mashup Score: 1
Jessica Bauman, MD, of the Fox Chase Cancer Center, discusses the REACH PC study of virtual versus in-person palliative care for non-small cell lung cancer (NSCLC) at ASCO 2025.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 40
The ASCO 2025 data from the IMFORTE and DeLLphi-304 studies in small cell lung cancer (SCLC) are changing the standard of care, Dr. Stephen Liu said.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How are IMFORTE and DeLLphi-304 changing the standard of care for SCLC? 🌟 In this insightful new interview, @StephenVLiu unpacks the #ASCO25 data and what it means for the treatment landscape. ➡️ Watch now: https://t.co/Td7fORIMP1 #lcsm #SCLC #ASCO2025 https://t.co/yizgsDFYX9
-
-
Mashup Score: 1ASCO 2025: Optimizing Amivantamab Treatment in NSCLC - 2 day(s) ago
Optimizing amivantamab use is critical, as it now has an indication in relapsed EGFR-mutated non–small cell lung cancer after treatment with osimertinib and in frontline treatment.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How can amivantamab use be optimized? ⭐ Don't miss this interview with @JennyCarlisleMD of @WinshipatEmory, @EmoryMedicine, who shares insights from her #ASCO25 presentation on optimizing therapy & minimizing AEs. ➡️ Watch: https://t.co/XnqHXn4lCM #lcsm #lungcancer https://t.co/ZFXHzi2Odk
-
-
Mashup Score: 1ASCO 2025: DART Trial Assesses Relationship Between ctDNA and Outcomes in Unresectable NSCLC - 3 day(s) ago
ctDNA may be a potential biomarker to identify high-risk patients with unresectable stage III non–small cell lung cancer (NSCLC) who could benefit from tailored interventions.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📊 Results from the first MRD analysis of DART, presented at #ASCO25, suggest that ctDNA may be a potential biomarker for identifying high-risk patients with unresectable stage III #NSCLC who could benefit from tailored interventions. ➡️ Read more: https://t.co/QaGCBpGnzy #lcsm https://t.co/zaBfnNYJyk
-
-
Mashup Score: 5Phase 3 DeLLphi-304 Trial: Taralatamab Significantly Improves OS, PFS in Previously Treated SCLC - 6 day(s) ago
Tarlatamab significantly improved overall survival and progression-free survival compared to chemotherapy for small cell lung cancer, according to ASCO 2025 data.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 ICYMI: Tarlatamab significantly improved OS, PFS, and PROs compared to chemotherapy as a second-line treatment for SCLC, according DeLLphi-304 results presented at #ASCO25 by @charlesrudin of @MSKCancerCenter. ➡️ Learn more: https://t.co/IQDhWrIfO3 #lcsm #SCLC #lungcancer https://t.co/SLdOBeIQR4
-
-
Mashup Score: 0
The IASLC study showed that 40% of respondents in North America indicate that treatment for lung cancer is often initiated before receipt of the results of biomarker testing.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📰 Catching up on #ASCO25 news? ⭐️ Don't miss this video interview with Matthew Smeltzer, PhD, of @UofMemphisSPH, who unpacks data on lung cancer biomarker testing in North America! 📺Watch now: https://t.co/X4oWNZr3nr #lcsm #NSCLC https://t.co/1KPGi09mit
-
-
Mashup Score: 0ASCO 2025: TROPION-Lung02 Data Frontline Dato-DXd Plus Pembrolizumab, With or Without Chemotherapy - 21 day(s) ago
Dato-DXd plus pembrolizumab with or without platinum chemotherapy shows promise as a frontline therapy for patients with advanced non–small cell lung cancer (NSCLC).
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Catching up on #lcsm news from #ASCO25? ⭐ Don't miss our coverage of the TROPION-Lung02 data presented by @benlevylungdoc of @hopkinskimmel. ➡️ Learn more about the findings: https://t.co/AHIjGKzBfe #lcsm #LungCancer https://t.co/PE3p0SmpkD
-
-
Mashup Score: 0
Cheryl Czerlanis, MD, chaired the ASCO 2025 session and gave a presentation on the role of family history and germline mutations in lung cancer risk.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🗨️ How can we overcome lung cancer screening challenges and embrace novel technologies at a global scale? 🌟 Cheryl Czerlanis, MD, of @UWCarbone, who chaired an #ASCO25 session on the topic, joined us to share her insights. ➡️ Watch: https://t.co/zcbWbqYupN #lcsm #LungCancer https://t.co/y8kbSrkFId
-
-
Mashup Score: 22FDA Approval of Taletrectinib for ROS1+ NSCLC: Dr. Liu Weighs In - 23 day(s) ago
Stephen Liu, MD, shares his insights on the recent FDA approval of taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC).
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 With the FDA's recent approval of taletrectinib for ROS1+ NSCLC, @StephenVLiu joined us to weigh in on the data behind the approval, what it means for the treatment landscape, and what could be on the horizon. ➡️ Watch now: https://t.co/efLEottTGm #lcsm #NSCLC #LungCancer https://t.co/V9Dq4IhGay
-
-
Mashup Score: 13ASCO 2025: Insights on CheckMate-816, IMforte, and DeLLphi-304 From Coral Olazagasti, MD - 24 day(s) ago
Thoracic oncology highlights and analysis from ASCO 2025, including CheckMate-816, IMforte, and DeLLphi-304 from Coral Olazagasti, MD, of the University of Miami.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Catching up on thoracic oncology news from #ASCO25? ⭐ Don't miss this insightful interview with @COlazagasti, who unpacks key updates in #NSCLC and #SCLC, and reflects on bringing practice-changing data back to the clinic! ➡️ Watch: https://t.co/M7aytTSkMJ #lcsm https://t.co/LgjfRYqiQc
-
💭 Does the type of early palliative care delivery affect quality of life improvements for patients with advanced NSCLC? 🎤 In this #ASCO25 interview, Jessica Bauman, MD, of @FoxChaseCancer, compares video versus in-person methods. ➡️ Watch now: https://t.co/OEygoOvapY #lcsm https://t.co/5TElo3OVVB